Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia

Haematologica

Volumn 85, Issue 7, 2000, Pages 704-710

  Munoz, L ^a   Lopez, O ^a   Martino, R ^a   Brunet, S ^a   Bellido, M ^a   Rubiol, E ^a   Sierra, J ^a   Nomdedeu, J F ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Acute lymphoblastic leukemia; Bcr abl; Flow cytometry; Minimal residual disease; RT PCR

Indexed keywords

ANTINEOPLASTIC AGENT; CD22 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PURIFICATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; BONE MARROW CELLS; FALSE NEGATIVE REACTIONS; FEMALE; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 0033868462     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Treatment of acute lymphoblastic leukemia
2. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel transgenic model for human Ph1-positive leukemias
3. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
4. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia
5. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
6. Guidelines for the characterization and publication of human malignant hematopoietic cell lines
7. Leukemia cell lines: In vitro models for the study of Philadelphia chromosome-positive leukemia
8. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
9. Performance evaluation of the FACS Count system: A dedicated system for clinical cellular analysis
10. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia
11. Flow cytometric analysis of normal B cell differentiation a frame of reference for the detection of minimal residual disease in precursor-B-ALL
12. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: Implications for minimal residual disease detection
13. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction
14. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia
15. Consistent amounts of acute leukemia-associated p190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis
16. Detection of BCR/ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction
17. Detection and significance of bcr-abl mRNA transcript and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia
18. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis
19. The immunologic detection of minimal residual disease in acute leukemia
20. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia
21. CD66 expression in acute leukemia
22. Detection of minimal residual disease in acute leukemia by flow cytometry
23. Reverse transcription/polymerase chain reaction (RT/PCR) amplification of small numbers of transcripts: The risk in misinterpreting negative results
24. Reversal of RT-PCR inhibition observed in heparinized clinical specimens
25. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
26. Distribution of ABL and BCR genes in cell nuclei of normal and irradiated lymphocytes
27. PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplanration in BCR-ABL-positive acute lymphoblastic leukaemia
28. Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia
29. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
30. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction
31. Graft versus leukemia (GVL) in therapy of acute lymphoblastic leukemia (ALL)
32. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR
33. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction
34. Competitive polymerase chain reaction to estimate the number of BCR/ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
35. A BCR/ABL kinase antagonist for chronic myelogenous leukemia: A promising path for progress emerges
36. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
37. Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection